A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A post-hoc pooled analysis of four semaglutide trials found a lower risk of cardiovascular death or worsening heart failure in patients with HFpEF, though cardiovascular death alone was not reduced. PICO summary and expert commentary.
A prespecified secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials examining whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by sex. PICO summary and expert commentary.
A 12-week pilot RCT comparing an 800 kcal/day very-low calorie diet, semaglutide, and their combination in 30 adults with type 2 diabetes. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial examining whether semaglutide 2.4 mg reduces cardiovascular and heart failure outcomes in patients with obesity and prevalent heart failure. PICO summary and expert commentary.
A small single-centre study found that adding a long-acting GLP-1 receptor agonist to metformin lowered BMI but did not show a significant between-group glycaemic advantage. PICO summary and expert commentary.
Secondary analysis of the SELECT trial: semaglutide 2.4 mg increased regression to normoglycaemia and reduced progression to diabetes in adults with overweight or obesity and cardiovascular disease, yet did not slow glycaemic progression over time. PICO summary and expert commentary.
A prespecified SELECT analysis shows semaglutide reduced cardiovascular events in overweight or obese adults without diabetes regardless of baseline HbA1c or HbA1c change. PICO summary and expert commentary.
A prespecified FLOW analysis found once-weekly semaglutide 1 mg lowered the composite of heart failure events or cardiovascular death by 27 percent in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.